Category: 3. Business

  • Samsung Redefines AI Search on Smart TVs With a Smarter Bixby Voice Assistant – Samsung Global Newsroom

    Samsung Redefines AI Search on Smart TVs With a Smarter Bixby Voice Assistant – Samsung Global Newsroom

    Enhanced by Generative AI, Bixby now offers a more conversational and personalized experience for TV users to get more from what they’re watching without leaving the screen

     

    Samsung Electronics today announced an update1 to its AI-powered Bixby feature on its 2025 TV lineup, introducing a more advanced Bixby voice assistant designed to make information discovery more natural, intuitive and seamless.

     

    “Samsung has led the global TV market for 19 consecutive years, and we continue to raise the bar by delivering meaningful innovation that enhances everyday experiences,” said Hun Lee, Executive Vice President of the Visual Display Business at Samsung Electronics. “With a smarter Bixby, we focused on making AI practical, helping viewers connect with content in smarter, more natural ways.”

     

     

    Ask Your TV Anything. A Smarter Bixby Answers

    A smarter Bixby voice assistant on Samsung TVs now delivers a more natural and personalized experience. With a smarter Bixby, users can easily wake it up by voice or by pressing the mic button to start a conversation — no commands, no menus, no typing.

     

    The new Bixby understands context and follow-up questions, enabling more fluid interactions that feel like a real conversation. Powered by Generative AI, Bixby can answer any questions you may have, whether you’re asking about general information, such as “How tall is Mount Everest?” or recommendations like “Please suggest chill playlists for a rainy day”. By simply asking, Bixby can help answer questions about on-screen content, as it retrieves the most relevant details and displays them on screen. It’s a smarter, faster way to get more out of your TV without breaking your viewing flow.

     

     

    Smarter Bixby Enhances Click To Search

    With this update, Bixby is now integrated into Click to Search, making it easier than ever to discover and explore entertainment and more, whether watching live TV, cable channels or Samsung TV Plus. Users can ask about an actor, a show or a broader topic — and receive answers instantly, right on their TV.

     

    Bixby even enables Click to Search to go beyond what’s on screen. For everyday questions such as “Tell me the recipe for making pasta” or “Do you know any good movies about chefs?” Bixby delivers contextual responses using external information. It’s search made simple.

     

    Effortless Home Device Management With Bixby and SmartThings

    Equipped with a smarter Bixby, Samsung TVs can detect, connect and control appliances with Samsung SmartThings enabled. By speaking directly to their screen, users can leverage the SmartThings ecosystem to execute voice commands, such as “Turn off the oven now,” or “Set the air conditioner to 25 degrees,” transforming their smart TV into a central hub for managing other smart home appliances.

     

    Moreover, Bixby is secured by Samsung Knox, the industry-leading security solution designed to protect users’ sensitive personal data. Users can enjoy AI-driven personalized features without worrying about privacy concerns, as no user voice data is stored on servers or TVs.

     

     

    Ongoing Support and Availability

    Smarter Bixby will be available on 2025 Samsung TVs, including Neo QLED, OLED, The Frame and QLED models, with availability starting in South Korea and extending to global markets in phases.

     

    Building on the integration of Bixby within Vision AI, Samsung will introduce a newly upgraded version of Vision AI in October 2025. This evolved Vision AI will be available through Samsung’s 7-year free Tizen OS Upgrade program, which ensures ongoing software enhancements and long-term support.

     

    For more information, visit www.samsung.com.

     

     

    1 The update will start rolling out in the U.S. on August 4, with plans to expand to four European countries (France, Germany, Italy, Spain) within August.

    Continue Reading

  • Transmission of liquidity shocks through non-bank financial intermediaries: Evidence from the International Banking Research Network

    As non-bank financial intermediaries (NBFIs) have become more important in recent decades, their involvement in funding markets as well as roles in financial crises have also increased. With substantial heterogeneity across NBFIs’ business models and striking differences in the composition of the NBFI sectors across countries, evidence on the transmission of liquidity shocks through NBFIs is still scarce. A new initiative of the International Banking Research Network
    (IBRN) includes 11 papers that provide extensive new insights about the rise of the NBFI sector and the roles of NBFIs in liquidity shock transmission, domestically, across borders, and across different financial markets. Some studies also investigate the transmission of shocks from NBFIs to the banking sector.

    Background on non-bank financial intermediary developments

    In the last two decades, NBFIs in the global financial system have gained substantial importance, both in absolute terms and relative to the traditional banking sector. According to the FSB (2024), by end-2023 the assets under management of the global NBFI sector were about 50% of the private global financial system, with assets of approximately $238.8 trillion. While many countries have banks as the single largest entity type, developments over the last two decades have left the collection of non-bank financial institutions of different types to be often as large as, or larger than, banks in terms of share of total domestic financial assets (Figure 1, reproduced from FSB 2024).

    Figure 1 Composition of total domestic financial assets across jurisdictions

    Source: Financial Stability Board 2024.
    Notes: Data as of 2023, for Russia as of 2020 (and not included in All and emerging market economies). Banks include all deposit-taking corporations. The percentages of OFI assets to GDP for the Cayman Islands (296,237), Luxembourg (19,248), Ireland (1,204), and the Netherlands (567) are not shown since they are particularly high compared to the rest of the jurisdictions.

    The heterogeneity of non-bank financial intermediaries is substantial, as some – like insurance companies – operate with generally low leverage and liquidity risk while others include more fragile investment funds and even riskier hedge funds. The key drivers of the growth of the overall NBFI sector have been investment funds (see Figure 2), which have more than doubled as a share of NBFI assets in the past two decades, even while the whole sector has grown. Most NBFIs are less transparent and less regulated than traditional banks. They have also been at the core of many financial crises or at least key amplifiers, such as in the Long-Term Capital Management (LTCM) crisis in 1998, AIG in 2008, the dash-for-cash in March 2020, and the UK gilt crisis in September 2022.

    Figure 2 Composition of total global non-bank financial intermediary assets

    Source: Own calculations based on Financial Stability Board 2024.
    Notes: 21 countries plus the euro area, which comprises for the latest data point the following 20 jurisdictions: Austria, Belgium, Croatia, Cyprus, Estonia, Finland, France, Germany, Greece, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Portugal, Slovakia, Slovenia, and Spain. Data for Russia are excluded. Other investment funds (OIFs) are investment funds other than MMFs, HFs and REITs. These include equity funds, fixed-income funds and other funds such as mixed funds, referenced investment funds, external debt investment funds, currency funds, asset allocation funds, etc. ‘Others’ include financial auxiliaries, HFs, REITs, trust companies, finance companies, broker-dealers, structured finance vehicles, central counterparties, captive financial institutions, money lenders and other OFIs (both identified and unidentified). Latest observation: 2023.

    What is behind the rise of the non-bank financial intermediaries?

    The rise of NBFIs has been attributed to structural changes in economies, such as technological changes in the financial sector and demographic shifts, leading to a secular interest rate decline and a search for yield by investors. Combined with tighter regulation of banks, especially higher capital requirements, this led to a shift in the intermediation of funding from the regulated banking sector to the less regulated ‘shadow banking sector’ (Claessens 2024). There is substantial evidence that this regulatory arbitrage contributed to the rise of the NBFI sector in the US (Irani et al. 2021, Gebauer and Mazelis 2023, and Hodula and Ngo 2024). Ultimately, liquidity demand is a core feature of non-bank intermediation, since the threat of capital redemption is key to aligning the incentives of investors with those of portfolio managers.

    Among the contributors to the International Banking Research Network initiative, Aramonte (2025) also focuses on liquidity demand associated with the privatisation of retirement planning and retirement risks in the US. In order to overcome agency problems in the growing delegated asset management, he argues that NBFIs need to be inherently fragile through a liquidity transformation in the spirit of Calomiris and Kahn (1991). For Sweden, Li and Myers (2025) find that demographic changes elevated the needs for capital-based retirement products and the search for yield during the low-interest rate period was also a major factor contributing to the growth, especially of pension funds.

    Exposure to and amplification of shocks through non-bank financial intermediaries

    Prior studies have argued that the open-end structure of investment funds can bring about a first-mover advantage to redeeming investors, leading to panic-induced withdrawals and elevated sensitivity of net inflows to funds’ underperformance (Chen et al. 2010), especially for corporate bond funds and funds invested in other illiquid securities. Additional important lessons come from the IBRN studies that focus on how liquidity shocks are amplified and transmitted. Marino-Montana et al. (2025) document that Colombian fixed-income funds with an open-end structure have an elevated flow-performance relationship. As a consequence, in periods of significant repricing of risks, such as the COVID crisis, especially illiquid funds experience significant net outflows and liquidity shortages, forcing these funds into fire sales.
    The liquidity transformation of open-end investment funds, together with stale pricing of illiquid securities, can also make fund flows susceptible to changes in monetary policy (Kuong et al. 2024). 

    A series of papers in the IBRN initiative consider monetary policy shocks as the example of liquidity shocks that impact NBFIs, with key quantitative findings summarised in Table 1. Reasonably large monetary policy shocks can induce significant changes in investment fund flows. Fecht and Kellers (2025) show that open-end investment funds in Germany – the third largest investment fund domicile in the euro area – experience significantly lower net flows in response to an unexpected monetary policy tightening by the European Central Bank. Hodula and Malovaná (2025) show that mutual fund flows in the Czech Republic are more sensitive to foreign monetary policy shocks — particularly those from the ECB — than to changes in domestic monetary policy. These effects are primarily driven by changes in inflows rather than redemptions and are significantly amplified during periods of domestic currency depreciation, which increases investor sensitivity to foreign interest rate differentials.

    Blanco et al. (2025) extend the analysis to a multi-country setting, comprising nine euro area countries, Switzerland, the UK, and the US, allowing for systematic comparison of the response of mutual fund flows to domestic and foreign monetary policy shocks across different currency blocks. Responses to domestic monetary policy shocks vary significantly across countries and lead, for instance, to increased bond-fund flows into Switzerland and the US, while flows to the euro area and the UK decline. They find similar responses to foreign monetary policy shocks. Interestingly, they document higher sensitivity of passively managed and/or foreign-domiciled funds.

    Table 1 Mutual funds: Effects of a 100 basis point contractionary monetary policy surprise

    Note: Global fund flows are to a multi-country sample comprising nine euro area countries, Switzerland, the UK, and the US (Blanco et al. 2025).

    Several IBRN contributions from across countries also highlight the heterogeneity of different types of fund investors in responding to return or interest rate shocks. Hodula and Malovaná (2025) find that the responses of investor sectors in the Czech Republic differ systematically with their investment horizons and liquidity preferences. Specifically, banks and investment funds — investors with higher liquidity needs — respond more strongly to short-term interest rate differentials and domestic monetary policy shocks, often driving net outflows. In contrast, firms and insurance companies — typically longer-term investors — are more responsive to long-term rate differentials and foreign monetary policy shocks, suggesting greater sensitivity to global yield conditions. Della Corte et al. (2025) inform the role of insurance companies as stabilising investors: when insurers withdraw for reasons unrelated to a fund’s (expected) performance, European funds with other long-term investors could compensate these outflows. Other investment funds left mostly with short-term investors suffered further outflows by these flightier investors.

    Spillovers from non-bank financial intermediaries’ liquidity tightening

    Liquidity crises at investment funds can lead to fire sales of their underlying assets, causing significant price pressure and market dry-ups (Falato et al. 2012b). Little is known, though, whether monetary policy-induced net outflows from funds also transmit to the securities market. In their IBRN contribution, Ben-Ze’ev et al. (2024) document for investment funds domiciled in Israel that in response to a local monetary policy tightening, retail investors withdraw particularly from bond funds but at the same time invest in money market funds. They find that the sales of fixed-income assets by affected bond funds temporarily impair the market liquidity of these securities. Ben Zeev et al. (2025) show that shocks to capital inflows from foreign financial institutions (FFIs) fundamentally also create persistent increases in convenience yields as measured by wedges between central bank monetary stance and market interest rates, revealing a significant channel through which global capital flows affect monetary transmission and asset pricing in integrated markets.

    With the rise of the NBFI sector, not only money market funds but also open-end investment funds, which usually maintain a relatively stable portfolio share of cash and cash equivalent holdings, become an important source of short-term refinancing for the banking sector in many countries (see European Central Bank 2025). This also gives rise to potential spillovers from NBFIs to the banking sector that several IBRN contributions further explore. Müller et al. (2025) investigate the impact of large-scale investment fund redemptions in Colombia on the demand for certificates of deposits (CDs) issued by the domestic banking sector. They show that banks, as a result of funds’ depressed demand for certificates of deposit, experienced significant constraints in their refinancing and had to tighten their credit conditions and cut back their lending.

    Moreover, outflows from investment funds, such as those induced by monetary policy shocks, can lead to a decline in wholesale deposits held by funds with banks and amplify the transmission of monetary policy through the deposit channel. Using granular data from Germany, Fecht and Kellers (2025) show that run-prone investment funds, which are particularly affected by outflows due to monetary policy tightening, reduce their cash buffers with banks disproportionately.

    Jara et al. (2025) focus on other NBFIs, namely pension funds, which play an important role in the Chilean financial system. They find that internationally invested pension funds in Chile offset capital outflows from Chile resulting from the flight to safety in case of a shock abroad and thereby stabilise funding to the local banking sector. However, they also document that in case of unexpected withdrawals from local pension funds, the liquidity shock also affects the refinancing of domestic banks.

    Concluding remarks

    The International Banking Research Network initiative, with its focus on the drivers of growth of NBFIs and the responses to shocks across countries, shows that the susceptibility of NBFIs in general, and investment funds in particular, to shocks and unexpected monetary policy changes depends very much on the NBFI type. Transmission of shocks, including monetary policy impulses, is amplified by the characteristics that increase the fragility of NBFIs. Investment funds rather than insurance companies, investment funds with less liquid asset holdings, and investment funds with more flighty investors experience larger outflows in response to a given shock. For example, a larger proportion of short-term investors, such as banks and other funds, heightens sensitivity to domestic monetary policy shocks. Conversely, funds primarily held by insurance companies and non-financial firms are more affected by foreign monetary policy shocks. Geographic domiciliation creates additional vulnerabilities, as funds domiciled abroad are more susceptible to domestic monetary policy shocks according to the Swiss National Bank’s study. Asset characteristics compound these effects: in Colombia, Germany, and the Czech Republic, funds with illiquid asset holdings and stale asset prices exhibit greater fragility and responsiveness to policy changes as investors benefit from first-mover advantage.

    The NBFI–bank nexus and associated spillovers represent a second critical dimension that varies substantially across countries depending on interlinkages in wholesale funding and institutional investor roles. Crisis-induced fund redemptions create direct banking sector pressures through multiple channels. In Colombia, such redemptions diminish fund demand for bank-issued certificates of deposit, tightening bank liquidity and credit conditions. Germany exhibits a similar pattern, where investment fund outflows resulting from monetary policy shocks and subsequent portfolio rebalancing lead to reduced wholesale deposit holdings by funds. By contrast, Chile demonstrates a stabilising dynamic where domestic pension funds help stabilise domestic bank funding during capital outflows, though unexpected withdrawals from these same pension funds can reverse this effect. Israel presents yet another pattern, where money market mutual funds benefit particularly from fund reallocation away from risky fixed-income funds during monetary interventions.

    These cross-country variations underscore that NBFI vulnerabilities and their transmission to the banking sector are highly dependent on domestic financial architecture and institutional arrangements.

    Authors’ note: The views expressed are those of the authors, and do not necessarily reflect the views of the Deutsche Bundesbank, the Eurosystem, the Federal Reserve Bank of New York, or the Federal Reserve System. The authors would like to thank the participants of the International Banking Research Network initiative on NBFIs and Liquidity for rich discussions and careful research content.

    References

    Aramonte, S (2025), “Liquidity imbalances in non-bank intermediation: Taming demand or bolstering supply?”, Federal Reserve Board.

    Ben-Ze’ev, N, S Ribon and R Stein (2024), “Monetary policy and the mutual fund market: Funding and liquidity”, Bank of Israel Discussion Paper 2024.11.

    Ben Zeev, N, N Ben-Zeev and D Nathan (2025), “Capital inflow shocks and convenience yields”, Bank of Israel.

    Blanco, S, M Koomen and P Yesin (2025), “Heterogeneous effects of monetary policy surprises on bond fund flows”, Swiss National Bank.

    Calomiris, C W and C M Kahn (1991), “The Role of Demandable Debt in Structuring Optimal Banking Arrangements”, The American Economic Review 81(3): 497–513.

    Chen, Q, I Goldstein and W Jiang (2010), “Payoff complementarities and financial fragility: Evidence from mutual fund outflows”, Journal of Financial Economics 97(2): 239–262.

    Claessens, S (2024), “Non-bank financial intermediation: Stock take of research, policy and data”, CEPR Discussion Paper No. 18945.

    Della Corte, V, R Gallo, T Makinen and F Palazzo (2025), “Beyond the surface: Open-ended funds’ investor base and their portfolio allocation”, Banca d’Italia.

    European Central Bank (2025), “Examining the dynamics of liquid asset holdings in the non-bank financial sector”, Financial Stability Review, May, Box 5, pp 73.

    Falato, A, I Goldstein and A Hortacsu (2021a), “Financial fragility in the COVID-19 crisis: The case of investment funds in corporate bond markets”, Journal of Monetary Economics 123: 35-52.

    Falato, A, A Hortaçsu, D Li and C Shin (2021b), “Fire‐sale spillovers in debt markets”, The Journal of Finance 76(6): 3055–3102.

    Fecht, F and M Kellers (2025), “Monetary policy, fragility, and fund flows”, Deutsche Bundesbank.

    FSB – Financial Stability Board (2024), Global Monitoring Report on Non-Bank Financial Intermediation.

    Gebauer, S and F Mazelis (2023), “Macroprudential regulation and leakage to the shadow banking sector”, European Economic Review 154, 10440.

    Goldstein, I, H Jiang and D T Ng (2017), “Investor flows and fragility in corporate bond funds”, Journal of Financial Economics 126(3): 592-613.

    Hodula, M and S Malovaná (2025), “Mutual fund flows in face of domestic and foreign monetary policy shocks: Evidence from supervisory data”, Czech National Bank working paper, forthcoming.

    Hodula, M and N A Ngo (2024), “Does macroprudential policy leak? Evidence from shadow bank lending in EU countries”, Economic Modelling 132, 106657.

    Irani, R M, R Iyer, R R Meisenzahl and J-L Peydró (2021), “The rise of shadow banking: Evidence from capital regulation”, The Review of Financial Studies 34(5): 2181-2235.

    Jara, A and D Moreno (2025), “Between stabilization and volatility: Domestic NBFIs and bank funding in emerging markets”, Banco Central de Chile.

    Kuong, J C F, J O’Donovan and J Zhang (2024), “Monetary policy and fragility in corporate bond mutual funds”, Journal of Financial Economics 161(August), 103931.

    Li, J and S Myers (2025), “Shadow banks or just not banks? Growth of the Swedish non-bank sector”, Sveriges Riksbank Working Paper.

    Ma, S, Y Peng, W Wu and F Zhu (2022), “Bank liquidity hoarding and corporate maturity mismatch: Evidence from China”, Research in International Business and Finance 63, 101776.

    Marino-Montana, J S, D Rodriguez-Novoa and C Sanchez-Quinto (2025), “Exploring the flow-performance relation in Colombian open-end investment funds”, Central Bank of Colombia.

    Müller, C, M O Busch, M Sarmiento and F Pinson-Puerto (2025), “Fragile wholesale deposits, liquidity risk, and banks’ maturity transformation”, BIS Working Papers No. 1263, Bank for International Settlement.

    Continue Reading

  • Skyrora gets UK launch license as first flight likely slips to 2026

    Skyrora gets UK launch license as first flight likely slips to 2026

    TAMPA, Fla. — Skyrora has become the first British company to secure a launch license from the U.K.’s Civil Aviation Authority (CAA), though a lack of available launch pads could push its first suborbital flight from SaxaVord Spaceport into 2026.

    The CAA license, announced Aug. 4, allows for up to 16 launches from SaxaVord using Skylark L, an 11-meter suborbital rocket with a 50-kilogram payload capacity.

    Skylark L flew for the first time in 2022 from Iceland using the company’s mobile launch facility. It reached 300 meters, well short of the 100-kilometer Kármán line, because of a software issue.

    The rocket is designed to de-risk technologies that will be used in Skyrora XL, a vehicle twice as tall and capable of placing up to 315 kilograms into low Earth orbit.

    While the company is exploring other sites, including international options that could use its mobile launch facility, Skyrora head of government affairs Alan Thompson said its priority remains flying from SaxaVord, located in Scotland’s Shetland Islands.

    “Unfortunately, earlier in the year, we were told that there was no longer availability to launch from either of the pads at SaxaVord,” Thompson said via email. 

    “Therefore, despite having a vehicle ready and a launch license, it is unlikely that Skyrora will be able to complete its launch from the U.K. this year.”

    He did not elaborate on the shortage of available pads.

    Inside Skyrora’s factory in Scotland, where engineers produce components for the company’s rockets. Credit: Skyrora

    Germany’s Rocket Factory Augsburg (RFA), which secured a CAA orbital license last year, postponed its maiden flight from SaxaVord to 2025 following a launchpad explosion during a static fire test.

    Scotland-based Orbex also aims to conduct its maiden launch from SaxaVord this year after halting work to develop a nearby spaceport, although it is still awaiting a license.

    Colin Macleod, the CAA’s head of space regulation, said during an Aug. 4 media briefing that German startup HyImpulse Technologies has an Air Navigation Order to fly a much smaller rocket up to 50 kilometers from SaxaVord.

    Skyrora first applied for a broader spaceflight activities license from the CAA in August 2022, expecting a nine- to 18-month review. A year later, it submitted a separate application focused on Skylark L to expedite the process, but still encountered delays.

    “The launch license process took longer than anticipated, but we understand that this is an industry-first for all parties involved,” Thompson said.

    “It is more important to get things right rather than do them quickly.”

    Going for orbit

    Thompson said two of the three stages for Skyrora XL are complete, with the first stage expected soon. The company plans to carry out integration tests for the XL vehicle next year, depending on manufacturing timelines.

    “Having completed the process for this sub-orbital launch, we hope this bodes well and helps to contribute towards a faster process for our orbital license,” he said.

    Macleod declined to give a timeframe for other licenses in the works during the media briefing.

    “They progress at the pace of, obviously, my assessment team, but also at the pace of the technical readiness of the operators, the maturity of the technology and how ready they are to move towards launch,” he said.

    Skyrora is the third rocket company to get a CAA launch license for space, following RFA and U.S.-based Virgin Orbit, which collapsed into bankruptcy shortly after an unsuccessful attempt to reach orbit in January 2023 from Spaceport Cornwall, in southwest England.

    Macleod said the regulator aims to license complex launch operations as early as possible, enabling “launchers to focus on our primary concern, which is safety to the public, and our second commitment, which is to ensure and support growth wherever possible.”

    He said “we haven’t had any operation which has been delayed due to a regulatory license decision, and all the licenses that we’ve issued so far have been ahead of technical readiness, or contractual readiness or things outside the regulator’s remit.”

    While Skylark L was originally intended to complete final checks on subsystems before their use in Skyrora XL, the company said it is seeing rising demand for its ability to provide up to six minutes of microgravity for experiments at a fraction of the cost of an orbital mission.

    The rocket’s inaugural U.K. flight is slated to carry a proof-of-concept mission for a space telemetry provider, demonstrating how Skylark L could be used to communicate with satellites.

    Continue Reading

  • Chubb Limited Announces Pricing of $1.25 Billion Senior Notes Offering by Subsidiary

    Chubb Limited Announces Pricing of $1.25 Billion Senior Notes Offering by Subsidiary

    Chubb Limited Announces Pricing of $1.25 Billion Senior Notes Offering by Subsidiary

    ZURICH, Aug. 4, 2025 /PRNewswire/ — Chubb Limited (NYSE: CB) announced today that its subsidiary, Chubb INA Holdings LLC, has priced a public offering of $1.25 billion of 4.90% senior notes due 2035 (the “Notes”). The Notes are guaranteed by Chubb Limited. 

    Chubb intends to use the net proceeds for general corporate purposes, including the repayment of a portion of the $1.5 billion of its outstanding 3.35% senior notes due May 3, 2026. 

    The joint book-running managers for the offering are Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC.  

    This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any of the senior notes or any other securities, nor will there be any offer, solicitation or sale of the senior notes or any other securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained by calling Citigroup Global Markets Inc. at 1-800-831-9146, Goldman Sachs & Co. LLC at 1-866-471-2526 or Wells Fargo Securities, LLC at 1-800-645-3751.

    Alternatively, the prospectus supplement and accompanying prospectus may be obtained by visiting EDGAR on the U.S. Securities and Exchange Commission (SEC) website at www.sec.gov.

    About Chubb
    Chubb is a world leader in insurance. With operations in 54 countries and territories, Chubb provides commercial and personal property and casualty insurance, personal accident and supplemental health insurance, reinsurance and life insurance to a diverse group of clients.  The company is defined by its extensive product and service offerings, broad distribution capabilities, exceptional financial strength and local operations globally. Parent company Chubb Limited is listed on the New York Stock Exchange (NYSE: CB) and is a component of the S&P 500 index. Chubb employs approximately 43,000 people worldwide.  Additional information can be found at: www.chubb.com.

    Cautionary Statement Regarding Forward-Looking Statements:

    Forward-looking statements made in this press release, such as statements regarding use of proceeds, reflect the company’s current views with respect to future events and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, which may cause actual results to differ materially from these statements.  Additional information regarding factors that could cause differences from these forward-looking statements appears in the company’s filings with the SEC.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

    SOURCE Chubb Limited

    For further information: Investor Contact, Karen Beyer: (212) 827-4445, karen.beyer@chubb.com, Media Contact, mediarelations@chubb.com

    Continue Reading

  • Assessing Tivozanib Efficacy in Metastatic RCC Treatment

    Assessing Tivozanib Efficacy in Metastatic RCC Treatment

    Treatment for metastatic renal cell carcinoma (RCC) continues to change with evolving options, including targeted therapies and immunotherapy combinations. Sumanta K. Pal, MD, chair of the Kidney and Bladder Cancer Disease Team, codirector of the Kidney Cancer Program, and professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center moderated a virtual Case-Based Roundtable event. He highlighted different dosing regimens for lenvatinib (Lenvima), as well as data from tivozanib (Fotivda) trials evaluating efficacy in relapsed/refractory RCC.

    Register today to join a Case-Based Roundtable near you.

    This article is part 2 of a 2-part series from a Case-Based Roundtable event.

    Targeted Oncology: Can you discuss what Study 218 (NCT03173560) showed for patients with relapsed/refractory RCC?

    Sumanta K. Pal, MD: This was a study I ran that looked at patients who had received a VEGF TKI [tyrosine kinase inhibitor] and possibly prior PD-1–based therapy. The goal of this trial was to see if you could mitigate the toxicity associated with lenvatinib and everolimus. I think that can be a tough regimen. The dose we usually give for refractory RCC is 18 mg, with 5 mg of everolimus. In this FDA mandated trial, we compared that to 14 mg and 5 mg, respectively. The primary end point of the study was to do a comparison of toxicities and response rate to see if they were equally efficacious.1

    What I think is interesting—and this was shown in our final publication—is that it’s clear if you’re going with a higher dose of lenvatinib, you’re getting a little bit more bang for your buck. What is also interesting is, if you look at the frequency of toxicities associated with these agents, there’s not a meaningful difference between the 2 [dose levels]. You would think by coming down by a whole 4 mg of lenvatinib, you’d mitigate some of the toxicity signal with these regimens, but that doesn’t appear to be the case.

    I think this is important because I see a lot of second opinions where physicians will start lenvatinib at a lower dose than what’s on label, and it may not necessarily be mitigating toxicity in the way that we think based on these data.

    What are the data for using tivozanib monotherapy in the metastatic RCC space?

    The pivotal TIVO-3 clinical trial [NCT02627963] was also a study I was involved with. One of the things I’d like to point out is that this study was not done in the era of checkpoint inhibitors or cabozantinib [Cabometyx]. This study compared tivozanib to sorafenib [Nexavar], and at the time, sorafenib was a very reasonable control arm. We didn’t have much else. But as this study evolved, we started to see more and more patients getting checkpoint inhibitors. Ultimately, this trial showed what I think is a pretty compelling signal for tivozanib over sorafenib. There was a tail on the Kaplan-Meier curve for progression-free survival [PFS].2 The response rate was better with tivozanib vs sorafenib, and this led to the approval of tivozanib in patients who received prior systemic treatment.3

    Can you discuss the newer data with tivozanib combinations for this patient population?

    At the 2024 European Society for Medical Oncology Congress, the TiNivo-2 study [NCT04987203] looked at combination of tivozanib and nivolumab [Opdivo] vs tivozanib monotherapy. There was a somewhat complicated dosing strategy for tivozanib. If you haven’t used it before, tivozanib is given at 1.34 mg orally on days 1 through 21 on the 28-day cycle. What’s interesting is that they did some phase 1 studies looking at tivozanib with nivolumab, and for some reason, that combination produced a very strong signal of hypertension. When the FDA gave comments around this study, they mandated that we use a lower dose of tivozanib of 0.89 mg with nivolumab. So it’s not necessarily a fully balanced comparison, but nonetheless, the goal of this study was to see whether, in patients who had received prior checkpoint inhibitors… there is any benefit in continuing the checkpoint inhibitor.4

    One of the things the study highlights is that this is a contemporary population of patients. Most of the patients in the study, about two-thirds, had only received 1 prior line therapy. A checkpoint inhibitor was the most recent therapy for most of these patients, and about a third of patients had received no prior VEGF TKIs. You can assume that for the most part, those are patients who got nivolumab plus ipilimumab [Yervoy].

    The patients who were entered onto this study had received prior nivolumab/ipilimumab or axitinib [Inlyta]/pembrolizumab [Keytruda]. Some had gotten nivolumab or cabozantinib in the second-line setting. But this was a good evaluation of second-line treatment by and large.

    What was the result of the TiNivo-2 trial?

    The key finding from the study was negative. There was no difference with a combination of tivozanib and nivolumab vs tivozanib in this in this setting. The Kaplan-Meier curves for PFS were fully overlapping. There was no subset of patients who benefited. You might think that perhaps a patient who has poor risk might benefit from the addition of further checkpoint inhibition, but we don’t see that the poor-risk category has that benefit. You might think that if patients receive more extensive prior targeted therapies, they might benefit more. That doesn’t appear to be the case.

    But what I think this study is important for, despite being negative, is the benchmark for how tivozanib can perform when it’s administered as second-line therapy. There was a [median] PFS of 9.2 months when we use tivozanib as second-line therapy. I think this is fairly comparable in many respects to drugs like cabozantinib and others we started to use in the second line.

    What other recent findings are relevant for tivozanib in patients with previously treated RCC?

    There was a more recent analysis that my junior faculty member at City of Hope presented at American Society of Clinical Oncology in June.5 He had a terrific poster that gave a lot of important data for tivozanib in patients who had received either prior immunotherapy or prior targeted therapy and immunotherapy. What [he showed is] if your patient, for instance, had just gotten prior nivolumab/ipilimumab, the response rate with tivozanib is on the order of 32%, so a pretty respectable response rate. On the other hand, if your patient had received prior axitinib/pembrolizumab, or cabozantinib/nivolumab, the response rate dwindles down a little bit to 22% there, but still a reasonable response. I would say this is a compelling signal that tivozanib has good efficacy in these second-line settings.

    Register today to join a Case-Based Roundtable near you.

    DISCLOSURES: Pal previously reported travel, accommodations, or expenses with CRISPR Therapeutics, Ipsen, and Exelixis.

    References:

    1. Pal SK, Puente J, Heng DYC, et al. Assessing the safety and efficacy of two starting doses of lenvatinib plus everolimus in patients with renal cell carcinoma: a randomized phase 2 trial. Eur Urol. 2022;82(3):283-292. doi:10.1016/j.eururo.2021.12.024

    2. Pal SK, Escudier BJ, Atkins MB, et al. Final overall survival results from a phase 3 study to compare tivozanib to sorafenib as third- or fourth-line therapy in subjects with metastatic renal cell carcinoma. Eur Urol. 2020;78(6):783-785. doi:10.1016/j.eururo.2020.08.007

    3. FDA approves tivozanib for relapsed or refractory advanced renal cell carcinoma. FDA. News release. Accessed August 4, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma

    4. Choueiri TK, Albiges L, Barthélémy P, et al. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study. Lancet. 2024;404(10460):1309-1320. doi:10.1016/S0140-6736(24)01758-6

    5. Chehrazi-Raffle A, Motzer RJ, Beckermann K, et al. Efficacy of second line (2L) treatment with tivozanib (tivo) as monotherapy or with nivolumab (nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (ipi)/nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the phase 3 TiNivo-2 study. J Clin Oncol. 2025;43(suppl 16):4540. doi:10.1200/JCO.2025.43.16_suppl.4540

    Continue Reading

  • Exclusive: Fed's Daly says time is nearing for rate cuts, may need more than two – Reuters

    1. Exclusive: Fed’s Daly says time is nearing for rate cuts, may need more than two  Reuters
    2. Fed’s Daly says two FOMC rate cuts in 2025 seem appropriate  TradingView
    3. Fed’s Daly says time is nearing for rate cuts, may need more than two  MarketScreener
    4. Exclusive-Fed’s Daly says time is nearing for rate cuts, may need more than two  MSN
    5. Fed’s Daly leans closer toward rate cuts, but still remains cautious  FXStreet

    Continue Reading

  • Libya's NOC signs memorandum of understanding with ExxonMobil after decade of inactivity – Reuters

    1. Libya’s NOC signs memorandum of understanding with ExxonMobil after decade of inactivity  Reuters
    2. ExxonMobil set to sign Libya deal, says US Embassy  Upstream Online
    3. Libya’s NOC signs memorandum of understanding with oil major Exxon Mobil after decade of activity halt  MSN
    4. Exxon set to sign offshore gas exploration deal with Libya, embassy says (XOM:NYSE)  Seeking Alpha

    Continue Reading

  • Nvidia Pushes Back on China AI Chip ‘Backdoor’ Fears

    Nvidia Pushes Back on China AI Chip ‘Backdoor’ Fears

    Nvidia (NVDA, Financials) is flatly denying Chinese claims that its new H20 AI chip could be used for hidden surveillance. The Cyberspace Administration of China pressed the company for answers after reports of potential backdoor features.

    The H20 was built specifically for the Chinese market after the US clamped down on high-end chip exports. It’s a toned?down version of the H100 and, Nvidia says, has no tracking hardware.

    Even with the political drama, demand is strong. Reuters says China recently ordered about 300,000 H20 chips from TSMC. Analysts think Beijing will keep buying while rushing to build its own alternatives from Huawei and others.

    For now, China’s regulator hasn’t announced any follow?up action. The chips will likely keep flowing, just under a brighter spotlight.

    This article first appeared on GuruFocus.

    Continue Reading

  • Vertex tops estimates on cystic fibrosis treatment strength, new products – Reuters

    1. Vertex tops estimates on cystic fibrosis treatment strength, new products  Reuters
    2. Vertex Reports Second Quarter 2025 Financial Results  Business Wire
    3. How Will VRTX Stock React To Its Upcoming Earnings?  Forbes
    4. Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call  Benzinga
    5. What To Expect From Vertex Pharmaceuticals’s (VRTX) Q2 Earnings  Yahoo Finance

    Continue Reading

  • Gates Foundation commits $2.5 billion to ‘ignored’ women’s health

    Gates Foundation commits $2.5 billion to ‘ignored’ women’s health

    The Gates Foundation will spend $2.5 billion by 2030 on women’s health, it said on Monday, with founder Bill Gates saying the area, including conditions from preeclampsia to menopause, had been neglected for too long.

    The investment is among its first big commitments since Gates announced earlier this year that he would give away his $200 billion fortune by 2045. It is around one-third more than the Foundation spent on women’s and maternal health research and development over the last five years.

    “Women’s health continues to be ignored, underfunded and sidelined. Too many women still die from preventable causes or live in poor health,” Gates said in a statement. “That must change.”

    The work will look at deeply under-researched areas that affect hundreds of millions of women in both high- and low-income countries, from preeclampsia and gestational diabetes to heavy menstrual bleeding, endometriosis and menopause.

    Investment will focus on five key areas: obstetric care and maternal immunization; maternal health and nutrition; gynaecological and menstrual health; contraceptive innovation; and sexually transmitted infection.

    The aim is to kickstart research, develop products, and ensure equitable access to them worldwide.

    The Foundation’s head of gender equality, Dr. Anita Zaidi, said that the field had been held back in part because of bias and a lack of data on key issues, such as how drugs cross into the uterus.

    “If you look at the literature, there may be only 10 women who’ve been studied, ever,” she told Reuters. “We don’t even have the answers to these basic questions.”

    Just one percent of the healthcare research and innovation spend went to female-specific conditions beyond cancer, a 2021 analysis by McKinsey & Co found.

    Zaidi acknowledged that the $2.5 billion was a “drop in the bucket” compared with what was needed and called on others to step in, including the private sector, philanthropists and governments.

    Continue Reading